Clinical Trial

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit or separately.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-01
Trial Details
NCT Number NCT07365826
Lead Sponsor Vaxcyte, Inc.
Conditions Pneumococcal Vaccines
Enrollment 1,390 participants
Start Date 2026-01-12
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-30